证券代码：300204 证券简称：舒泰神 公告编号：2025-082 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会无增加、变更、否决提案的情况，本次股东会不涉及变更前 次股东会决议。 2、本次股东会以现场投票、网络投票相结合的方式召开。 3、为尊重中小投资者利益，提高中小投资者对公司股东会决议事项的参与 度，本次股东会对中小投资者的表决进行单独计票，中小投资者是指除上市公司 董事、高级管理人员以及单独或者合计持有公司5%以上股份的股东以外的其他 股东。 一、会议召开和出席情况 1、会议通知情况 舒泰神（北京）生物制药股份有限公司 2025 年第三次临时股东会决议公告 出席公司 2025 年第三次临时股东会的股东（或委托代理人）587 人，代表 股份 150,641,202 股，占公司有表决权股份总数的 31.5299%。其中，参加现场会 议的股东（或委托代理人）3 人，代表股份 148,171,063 股，占公司有表决权股 份总数的 31.0129%；通过网络投票的股东（或委托代理人）584 人，代表股份 2,470,139 股， ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.:010-50867666 传真/Fax:010-56916450 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于舒泰神（北京）生物制药股份有限公司 2025 年第三次临时股东会的法律意见书 康达股会字【2025】第 0490 号 致：舒泰神（北京）生物制药股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《规则》"）、《深圳证券交易所上市公司股东会网 络投票实施细则》（以下简称"《实施细则》"）、《舒泰神（北京）生物制药 股份有限公司章程》（以下简称"《公司章程》"）及舒泰神（北 ...

数据显示，东方阿尔法基金旗下1只基金重仓舒泰神。东方阿尔法健康产业混合发起A（024357）三季 度增持22.3万股，持有股数23.95万股，占基金净值比例为6.08%，位居第八大重仓股。根据测算，今日 浮亏损失约39.51万元。连续5天下跌期间浮亏损失176.72万元。 东方阿尔法健康产业混合发起A（024357）成立日期2025年6月12日，最新规模3539.51万。成立以来亏 损4.69%。 东方阿尔法健康产业混合发起A（024357）基金经理为孟昱。 11月24日，舒泰神跌5.17%，截至发稿，报30.27元/股，成交3.80亿元，换手率2.67%，总市值144.62亿 元。舒泰神股价已经连续5天下跌，区间累计跌幅18.78%。 资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 从基金十大重仓股角度 截至发稿，孟昱累计任 ...

Core Viewpoint - The company has recently obtained a new drug production license from the Beijing Municipal Drug Administration, which is a significant regulatory milestone for its operations [2]. Group 1 - The company, Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd., has received a drug production license, allowing it to enhance its manufacturing capabilities [2]. - Following the acquisition of the drug production license, the company applied for a new business license from the Beijing Economic and Technological Development Zone Market Supervision Administration [2]. - The company has completed the business registration change procedures and obtained a new "Enterprise Legal Person Business License" from the relevant authority [2].

证券代码：300204 证券简称：舒泰神 公告编号：2025-081 舒泰神（北京）生物制药股份有限公司 关于换发药品生产许可证及营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、舒泰神（北京）生物制药股份有限公司（以下简称"公司"）于近期取 得了北京市药品监督管理局换发的药品生产许可证，主要信息如下： 企业名称：舒泰神（北京）生物制药股份有限公司 北京市北京经济技术开发区经海二路 36 号：口服溶液剂、散剂、片剂、治 疗用生物制品*** 社会信用代码：911100007423131451 注册地址：北京市北京经济技术开发区经海二路 36 号 法定代表人：周志文 企业负责人：王超 质量负责人：刘晓宁 有效期至：2030 年 11 月 02 日 许可证编号：京 20150112 分类码：AhsBsCs 生产地址和生产范围： 北京市北京经济技术开发区瑞合西一路 7 号院（北京昭衍生物技术有限公 司）：治疗用生物制品*** 二、基于上述药品生产许可证信息，根据《药品生产监督管理办法》的要求， 公司向北京经济技术开发区市场监督管理局申请换发了营业执照 ...

Core Points - The Shanghai Composite Index is at 3948.89 points with a slight increase of 0.05% as of 10:33 AM, and the total trading volume of A-shares is 851.994 billion yuan [1] - A total of 98 A-shares have seen their 5-day moving average cross below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stocks with Significant Moving Average Crosses - Bawei Storage (688525) has a 5-day moving average of 122.55 yuan, which is 2.96% lower than its 10-day moving average of 126.29 yuan, with a current price of 113.88 yuan, down 3.24% today [1] - Jinkai Biological (301509) shows a 5-day moving average of 37.52 yuan, down 1.69% from its 10-day moving average of 38.17 yuan, currently priced at 34.13 yuan, down 6.49% [1] - Shutaishen (300204) has a 5-day moving average of 35.59 yuan, which is 1.41% lower than its 10-day moving average of 36.09 yuan, with a current price of 33.40 yuan, down 2.34% [1] Group 2: Additional Stocks with Moving Average Crosses - Tongli Rising (605286) has a 5-day moving average of 42.55 yuan, down 1.39% from its 10-day moving average of 43.14 yuan, currently priced at 40.40 yuan, down 0.20% [1] - Ziran (605080) shows a 5-day moving average of 24.27 yuan, which is 1.25% lower than its 10-day moving average of 24.58 yuan, currently priced at 23.43 yuan, down 1.88% [1] - Yema Battery (605378) has a 5-day moving average of 25.22 yuan, down 1.23% from its 10-day moving average of 25.53 yuan, currently priced at 24.03 yuan, down 0.62% [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 舒泰神（北京）生物制药股份有限公司（以下简称"公司"）第六届董事会第 十一次会议审议通过了《关于提请召开公司 2025 年第三次临时股东会的议案》， 本次股东会将于 2025 年 11 月 24 日采用现场表决与网络投票相结合的方式召开。 《关于召开 2025 年第三次临时股东会的通知》已于 2025 年 11 月 07 日刊登于中国 证监会指定的创业板信息披露网站。现将会议有关事项提示如下： 一、召开会议的基本情况 证券代码：300204 证券简称：舒泰神 公告编号：2025-080 舒泰神（北京）生物制药股份有限公司 关于召开 2025 年第三次临时股东会的提示性公告 1、股东会届次：2025 年第三次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市 公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关 规定。 4、会议时间： （1）现场会议时间：20 ...

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.02% on November 19, with a trading price of 34.02 CNY per share, reflecting a significant drop in recent trading days despite a substantial year-to-date increase of 359.11% [1] Company Overview - Shuyou Shen (Beijing) Biopharmaceutical Co., Ltd. is primarily engaged in the research, production, and sales of biological products and some chemical drugs, with its main revenue sources being the injection of mouse nerve growth factor (Sutai) at 59.17%, compound polyethylene glycol electrolyte powder at 33.19%, and others at 7.63% [1] - The company was established on August 16, 2002, and went public on April 15, 2011 [1] Financial Performance - For the period from January to September 2025, Shuyou Shen reported an operating income of 181 million CNY, a year-on-year decrease of 30.82%, and a net profit attributable to shareholders of -30.69 million CNY, a decline of 227.71% [2] - The company has cumulatively distributed 771 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3] Shareholder Structure - As of September 30, 2025, the number of shareholders increased to 46,500, a rise of 46.97%, while the average circulating shares per person decreased by 31.98% to 9,745 shares [2] - Among the top ten circulating shareholders, notable changes include a decrease in holdings by the third-largest shareholder, Xingquan Helun Mixed A, by 3.45 million shares, and an increase in holdings by the fifth-largest shareholder, Xingquan Heyi Mixed A, by 338,750 shares [3] Market Activity - The stock has seen significant trading activity, with a net outflow of 29.42 million CNY from major funds on November 19, and it has appeared on the trading leaderboard eight times this year, with the most recent instance on October 31, where it recorded a net buy of 373 million CNY [1]

截至11月17日收盘，创新药概念下跌1.72%，位居概念板块跌幅榜前列，板块内，科兴制药、舒泰神、 昂利康等跌幅居前，股价上涨的有33只，涨幅居前的有富祥药业、海南海药、百花医药等，分别上涨 12.14%、10.04%、8.63%。 | 603858 | 步长制药 | -2.89 | 0.96 | -906.39 | | --- | --- | --- | --- | --- | | 301075 | 多瑞医药 | -2.17 | 1.99 | -894.32 | | 301408 | 华人健康 | -2.92 | 22.50 | -887.82 | | 600479 | 千金药业 | -1.90 | 1.87 | -871.50 | | 000597 | 东北制药 | -1.54 | 1.20 | -835.15 | | 002099 | 海翔药业 | 1.1 1 | 1.30 | -831.28 | | 301333 | 诺思格 | -1.53 | 3.36 | -788.71 | | 300575 | 中旗股份 | 0.15 | 2.31 | -781.84 | | 300026 | 红日药业 | -1 ...

Group 1 - The cell immunotherapy sector experienced a decline of 1.87%, ranking among the top losers in the concept sector, with companies like Shutaishen, Jimin Health, and Puris leading the declines [1][2] - Among the concept stocks, Baohua Pharmaceutical, ST Zhongzhu, and Laimei Pharmaceutical saw the highest gains, with increases of 8.63%, 4.80%, and 0.93% respectively [1][3] - The cell immunotherapy sector faced a net outflow of 1.658 billion yuan, with 54 stocks experiencing net outflows, and 8 stocks seeing outflows exceeding 50 million yuan [1][2] Group 2 - The top net outflow stocks in the cell immunotherapy sector included Shutaishen with a net outflow of 284.46 million yuan, followed by Hengrui Medicine, Hanyu Pharmaceutical, and Fosun Pharmaceutical with outflows of 236.06 million yuan, 124.39 million yuan, and 104.04 million yuan respectively [1][2] - Conversely, the stocks with the highest net inflows included Baohua Pharmaceutical, Boji Pharmaceutical, and Yuekang Pharmaceutical, with inflows of 79.05 million yuan, 13.46 million yuan, and 4.04 million yuan respectively [1][3] - The trading volume for Shutaishen was 12.35%, indicating significant trading activity despite the decline in stock price [2][3]